Single Cell Gene Expression Profiling in Alzheimer's Disease

NeuroRx

Volumn 3, Issue 3, 2006, Pages 302-318

  Ginsberg, Stephen D ^a,b   Che, Shaoli ^a,b   Counts, Scott E ^c   Mufson, Elliott J ^c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aging; Microarray; mild cognitive impairment; molecular fingerprint; neurodegeneration; postmortem human brain; qPCR; RNA amplification

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLUTAMINE; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE; PRESENILIN 1; PROTEIN KINASE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CADAVER; CELL POPULATION; CELL TYPE; COGNITIVE DEFECT; DISEASE COURSE; DNA MICROARRAY; FUNCTIONAL GENOMICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HIPPOCAMPUS; HUMAN; NEOCORTEX; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA ANALYSIS; SENILE PLAQUE; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MUTATION; NEURONS; PRESENILIN-1; PRESENILIN-2; TAU PROTEINS;

EID: 33745416559     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2006.05.007     Document Type: Article

References (210)

1. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., et al. Prevalence of Alzheimer's disease in a community population of older persons. higher than previously reported. JAMA 262 (1989) 2256-2551
2. Hebert L.E., Beckett L.A., Scherr P.A., and Evans D.A. Annual incidence of Alzheimer's disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 15 (2001) 169-173
3. Ginsberg S.D., Schmidt M.L., Crino P.B., Eberwine J.H., Lee V.M.-Y., and Trojanowski J.Q. Cerebral cortex. neurodegenerative and age-related changes in structure and function of cerebral cortex. In: Peters A., and Morrison J.H. (Eds). Molecular pathology of Alzheimer's disease and related disorders Vol 14 (1999), Kluwer Academic/Plenum, New York 203-653
4. Selkoe D.J. Alzheimer's disease. genotypes, phenotypes, and treatments. Science 275 (1997) 630-631
5. Trojanowski J.Q., and Lee V.M. The Alzheimer's brain. finding out what's broken tells us how to fix it. Am J Pathol 167 (2005) 1183-1188
6. Mufson E.J., Counts S.E., Fahnestock M., and Ginsberg S.D. In: (Dawbarn D., and Allen S.J. (Eds). NGF family of neurotrophins and their receptors. early involvement in the progression of Alzheimer's disease. In Neurobiology of Alzheimer's disease 3rd ed (2006), Oxford University Press, Oxford, UK
7. Mufson E.J., Bothwell M., and Kordower J.H. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease. a quantitative analysis across subregions of the basal forebrain. Exp Neurol 105 (1989) 221-232
8. Mufson E.J., Bothwell M., Hersh L.B., and Kordower J.H. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain. colocalization with cholinergic neurons. J Comp Neurol 285 (1989) 196-217
9. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., and Delong M.R. Alzheimer's disease and senile dementia. loss of neurons in the basal forebrain. Science 215 (1982) 1237-1239
10. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
11. Hyman B.T., van Hoesen G.W., Damasio A.R., and Barnes C.L. Alzheimer's disease. cell-specific pathology isolates the hippocampal formation. Science 225 (1984) 1168-1170
12. Hyman B.T., van Hoesen G.W., and Damasio A.R. Memory-related neural systems in Alzheimer's disease. an anatomic study. Neurology 40 (1990) 1721-1730
13. Hof P.R., and Morrison J.H. The aging brain. morphomolecular senescence of cortical circuits. Trends Neurosci 27 (2004) 607-613
14. Hyman B.T., and Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. J Neuropathol Exp Neurol 56 (1997) 1095-1097
15. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II: Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
16. Berchtold N.C., and Cotman C.W. Evolution in the conceptualization of dementia and Alzheimer's disease. Greco-Roman period to the 1960s. Neurobiol Aging 19 (1998) 173-189
17. Alzheimer A. Uber eine eigenartige Erkrangkung der Hirnrinde. All Z Psychiatr 64 (1907) 146-148
18. Skovronsky D.M., Lee V.M.-Y., and Trojanowski J.Q. Neurodegenerative diseases. new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 1 (2006) 151-170
19. Cohen A.S., and Connors L.H. The pathogenesis and biochemistry of amyloidosis. J Pathol 151 (1987) 1-10
20. Iwai A., Yoshimoto M., Masliah E., and Saitoh T. Non-Aβ component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34 (1995) 10139-10145
21. Masliah E., Iwai A., Mallory M., Ueda K., and Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 148 (1996) 201-210
22. Schmidt M.L., DiDario A.G., Otvos Jr. L., Hoshi M., Kant J.A., Lee V.M.-Y., et al. Plaque-associated neuronal proteins. a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain. Exp Neurol 130 (1994) 311-322
23. Pasinetti G.M. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease. the role of the complement system. Neurobiol Aging 17 (1996) 707-716
24. Atwood C.S., Martins R.N., Smith M.A., and Perry G. Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins. Peptides 23 (2002) 1343-1350
25. Glenner G.G., and Wong C.W. Alzheimer's disease. initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120 (1984) 885-890
26. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 82 (1985) 4245-4249
27. Perlmutter L.S., Barron E., and Chui H.C. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett 119 (1990) 32-36
28. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.-H.C., and Brosnan C.F. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7 (1993) 75-83
29. Itagaki S., McGeer P.L., Akiyama H., Zhu S., and Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J Neuroimmunol 24 (1989) 173-182
30. Vehmas A.K., Kawas C.H., Stewart W.F., and Troncoso J.C. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24 (2003) 321-331
31. Ginsberg S.D., Crino P.B., Lee V.M.-Y., Eberwine J.H., and Trojanowski J.Q. Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ann Neurol 41 (1997) 200-209
32. Iwatsubo T., Saido T.C., Mann D.M.A., Lee V.M.-Y., and Trojanowski J.Q. Full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid β42(43) deposit in diffuse plaques. Am J Pathol 149 (1996) 1823-1830
33. Masliah E., Terry R.D., Mallory N., Alford M., and Hansen L.A. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol 137 (1990) 1293-1297
34. Mufson E.J., Chen E.Y., Cochran E.J., Beckett L.A., Bennett D.A., and Kordower J.H. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158 (1999) 469-490
35. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 (2003) 1495-1500
36. Bussiere T., Friend P.D., Sadeghi N., Wicinski B., Lin G., Bouras C., et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 112 (2002) 75-91
37. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and LaFerla F.M. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
38. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., et al. Intraneuronal Alzheimer A{β}42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161 (2002) 1869-1879
39. Yang A.J., Knauer M., Burdick D.A., and Glabe C. Intracellular Aβ 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem 270 (1995) 14786-14792
40. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der Kolk N., et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165 (2004) 1289-1300
41. Leverenz J.B., and Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients. a regional quantitative analysis. Exp Neurol 150 (1998) 296-304
42. Hirayama A., Horikoshi Y., Maeda M., Ito M., and Takashima S. Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome. Brain Dev 25 (2003) 180-185
43. Rovelet-Lecrux A., Hannequin D., Raux G., Meur N.L., Laquerriere A., Vital A., et al. APP locus duplication causes autosomal dominant early-onset Alzheimer's disease with cerebral amyloid angiopathy. Nat Genet 38 (2006) 24-26
44. Selkoe D.J. Amyloid-β-protein and the genetics of Alzheimer's disease. J Biol Chem 271 (1996) 18295-18298
45. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
46. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
47. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373 (1995) 523-527
48. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
49. Finckh U., Kuschel C., Anagnostouli M., Patsouris E., Pantes G.V., Gatzonis S., et al. Novel mutations and repeated findings of mutations in familial Alzheimer's disease. Neurogenetics 6 (2005) 85-89
50. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
51. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
52. Kovacs D.M., Fausett H.J., Page K.J., Kim T.-W., Moir R.D., Merriam D.E., et al. Alzheimer-associated presenilins 1 and 2. neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 2 (1996) 224-229
53. Lah J.J., Heilman C.J., Nash N.R., Rees H.D., Yi H., Counts S.E., et al. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci 17 (1997) 1971-1980
54. Iwatsubo T. The gamma-secretase complex. machinery for intramembrane proteolysis. Curr Opin Neurobiol 14 (2004) 379-383
55. Pasternak S.H., Bagshaw R.D., Guiral M., Zhang S., Ackerley C.A., Pak B.J., et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J Biol Chem 278 (2003) 26687-26894
56. Duff K., Eckman C., Zehr C., Yu X., Prada C.-M., Perez-tur J., et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
57. Citron M., Westaway D., Xia W., Carlson G., Levesque G., Johnson-Wood K., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 3 (1997) 67-72
58. Iwatsubo T., Okada A., Suzuki N., Mizusawa N., Nukina N., and Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals. evidence that an initially deposited species is Aβ42(43). Neuron 13 (1994) 45-53
59. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation. implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
60. Jin L.-W., Maezawa I., Vincent I., and Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-{β} precursor protein in neurons with Niemann-Pick Type C defects is associated with endosomal abnormalities. Am J Pathol 164 (2004) 975-985
61. Hauser E.R., and Pericak-Vance M.A. Genetic analysis for common complex disease. Am Heart J 140 (2000) S36-S44
62. Bently D.R., and Dunham I. Mapping human chromosomes. Curr Opin Genet Dev 5 (1995) 328-334
63. Pericak-Vance M.A., Grubber J., Bailey L.R., Hedges D., West S., Santoro L., et al. Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol 35 (2000) 1343-1352
64. Olson J.M., Goddard K.A., and Dudek D.M. A second locus for very-late-onset Alzheimer's disease. a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 71 (2002) 154-161
65. Grupe A., Li Y., Rowland C., Nowotny P., Hinrichs A.L., Smemo S., et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer's disease. Am J Hum Genet 78 (2006) 78-88
66. Schmitz C., Rutten B.P.F., Pielen A., Schafer S., Wirths O., Tremp G., et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164 (2004) 1495-1502
67. Couchie D., Mavilia C., Georgieff I.S., Liem R.K., Shelanski M.L., and Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci USA 89 (1992) 4378-4381
68. Binder L.I., Frankfurter A., and Rebhun L.I. The distribution of tau in the mammalian central nervous system. J Cell Biol 101 (1985) 1371-1378
69. Goedert M., and Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739 (2005) 240-250
70. Goedert M., Spillantini M.G., Potier M.C., Ulrich J., and Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats. differential expression of tau protein mRNAs in human brain. EMBO J 8 (1989) 393-399
71. Goedert M., Spillantini M.G., Jakes R., Rutherford D., and Crowther R.A. Multiple isoforms of human microtubule-associated protein tau. sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989) 519-526
72. Goode B.L., and Feinstein S.C. Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol 124 (1994) 769-782
73. Ginsberg S.D., Che S., Counts S.E., and Mufson E.J. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 96 (2006) 1401-1408
74. Drecshel D.N., Hyman A.A., Cobb M.H., and Kirschner M. Modulation of the dynamic instability of tubulin assembly by the microtubule associated protein tau. Mol Biol Cell 3 (1992) 1147-1154
75. Kosik K.S., and Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 1739 (2005) 298-310
76. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270 (1995) 823-829
77. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43 (1998) 815-825
78. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
79. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001) 1121-1159
80. Ingram E.M., and Spillantini M.G. Tau gene mutations. dissecting the pathogenesis of FTDP-17. Trends Mol Med 8 (2002) 555-562
81. Mott R.T., Dickson D.W., Trojanowski J.Q., Zhukareva V., Lee V.M., Forman M., et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 64 (2005) 420-428
82. Spillantini M.G., Bird T.D., and Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17. a new group of tauopathies. Brain Pathol 8 (1998) 387-402
83. Bergmann M., Kuchelmeister K., Schmid K.W., Kretzschmar H.A., and Schroder R. Different variants of frontotemporal dementia. a neuropathological and immunohistochemical study. Acta Neuropathol (Berl) 92 (1996) 170-179
84. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282 (1998) 1914-1917
85. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.-A., et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86 (2003) 582-590
86. Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., and Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25 (2005) 5446-5454
87. Gotz J., Chen F., Barmettler R., and Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276 (2001) 529-534
88. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy. (P301L). J Neurosci 25 (2005) 10637-10647
89. Ikeda M., Shoji M., Kawarai T., Kawarabayashi T., Matsubara E., Murakami T., et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol 166 (2005) 521-531
90. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 26 (2005) 355-361
91. Strittmatter W.J., and Roses A.D. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 92 (1995) 4725-4727
92. Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C., Harrell L.E., et al. ApoE-4 and age at onset of Alzheimer's disease. the NIMH genetics initiative. Neurology 48 (1997) 139-147
93. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Aggarwal N.T., Arnold S.E., et al. Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60 (2003) 246-252
94. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
95. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell Jr. P.C., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat Genet 7 (1994) 180-184
96. Mahley R.W. Apolipoprotein E. cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
97. Lahiri D.K. Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J Mol Neurosci 23 (2004) 225-233
98. Benzing W.C., and Mufson E.J. Apolipoprotein E immunoreactivity within neurofibrillary tangles. relationship to tau and PHF in Alzheimer's disease. Exp Neurol 132 (1995) 162-171
99. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.-M., Salvesen G.S., Pericak-Vance M., et al. Binding of human apolipoprotein E to synthetic amyloid β peptide. isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 90 (1993) 8098-8102
100. Wisniewski T., Castano E.M., Golabek A., Vogel T., and Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145 (1994) 1030-1035
101. Sanan D.A., Weisgraber K., Russell S.J., Mahley R.W., Huang D., Saunders A., et al. Apolipoprotein E associates with Aβ amyloid peptide to form novel monofibrils. isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94 (1994) 860-869
102. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.-M., Jakes R., et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau. implications for Alzheimer's disease. Proc Natl Acad Sci USA 91 (1994) 11183-11186
103. Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541 (1991) 163-166
104. Bao F., Arai H., Matsushita S., Higuchi S., and Sasaki H. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. NeuroReport 7 (1996) 1733-1739
105. Dickey C.A., Loring J.F., Montgomery J., Gordon M.N., Eastman P.N., and Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23 (2003) 5219-5226
106. Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice. up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13 (2004) 1225-1240
107. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., and Landfield P.W. Incipient Alzheimer's disease. microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101 (2004) 2173-2178
108. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., and Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1. transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70 (2002) 462-473
109. Loring J.F., Wen X., Lee J.M., Seilhamer J., and Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol 20 (2001) 683-695
110. Lukiw W.J. Gene expression profiling in fetal, aged, and Alzheimer hippocampus. a continuum of stress-related signaling. Neurochem Res 29 (2004) 1287-1297
111. Minagar A., Shapshak P., Duran E.M., Kablingerm A.S., Alexander J.S., Kelley R.E., et al. HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia. gene expression review. J Neurol Sci 224 (2004) 3-17
112. Roy Walker P., Smith B., Liu Q.Y., Fazel Famili A., Valdes J.J., Liu Z., et al. Data mining of gene expression changes in Alzheimer brain. Artif Intell Med 31 (2004) 137-154
113. Katsel P.L., Davis K.L., and Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol 63 (2005) 41-82
114. Marcotte E.R., Srivastava L.K., and Quirion R. cDNA microarray and proteomic approaches in the study of brain diseases. focus on schizophrenia and Alzheimer's disease. Pharmacol Ther 100 (2003) 63-74
115. Ricciarelli R., d'Abramo C., Massone S., Marinari U., Pronzato M., and Tabaton M. Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life 56 (2004) 349-354
116. Blalock E.M., Chen K.C., Stromberg A.J., Norris C.M., Kadish I., Kraner S.D., et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease. statistical reliability and functional correlation. Aging Res Rev 4 (2005) 481-512
117. Ginsberg S.D. RNA amplification strategies for small sample populations. Methods 37 (2005) 229-237
118. Ginsberg S.D., Hemby S.E., Mufson E.J., and Martin L.J. Neuroanatomical tract tracing 3. Molecules-neurons-systems. In: Zaborszky L., Wouterlood F., and Lanciego J.L. (Eds). Cell and tissue microdissection in combination with genomic and proteomic applications (2006), Springer/Kluwer/Plenum, New York 109-141
119. Counts S.E., Chen E.Y., Che S., Ikonomovic M.D., Wuu J., Ginsberg S.D., et al. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord 21 (2006) 205-214
120. Ginsberg S.D., Che S., Wuu J., Counts S.E., and Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97 (2006) 475-487
121. Fasulo W.H., and Hemby S.E. Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J Neurochem 87 (2003) 205-219
122. Tang W.X., Fasulo W.H., Mash D.C., and Hemby S.E. Molecular profiling of midbrain dopamine regions in cocaine overdose victims. J Neurochem 85 (2003) 911-924
123. Greene J.G., Dingledine R., and Greenamyre J.T. Gene expression profiling of rat midbrain dopamine neurons. implications for selective vulnerability in parkinsonism. Neurobiol Dis 18 (2005) 19-31
124. Kamme F., Salunga R., Yu J., Tran D.T., Zhu J., Luo L., et al. Single-cell microarray analysis in hippocampus CA1. demonstration and validation of cellular heterogeneity. J Neurosci 23 (2003) 3607-3615
125. Luo L., Salunga R.C., Guo H., Bittner A., Joy K.C., Galindo J.E., et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med 5 (1999) 117-122
126. Ginsberg S.D., and Che S. Combined histochemical staining, RNA amplification, regional, and single cell analysis within the hippocampus. Lab Invest 84 (2004) 952-962
127. Vincent V.A., DeVoss J.J., Ryan H.S., and Murphy Jr. G.M. Analysis of neuronal gene expression with laser capture microdissection. J Neurosci Res 69 (2002) 578-586
128. Ginsberg S.D., Elarova I., Ruben M., Tan F., Counts S.E., Eberwine J.H., et al. Single cell gene expression analysis. implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res 29 (2004) 1054-1065
129. Ginsberg S.D., and Che S. Expression profile analysis within the human hippocampus. comparison of CA1 and CA3 pyramidal neurons. J Comp Neurol 487 (2005) 107-118
130. Bonner R.F., Emmert-Buck M., Cole K., Pohida T., Chuaqui R., Goldstein S., et al. Laser capture microdissection. molecular analysis of tissue. Science 278 (1997) 1481-1483
131. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., et al. Laser capture microdissection. Science 274 (1996) 998-1001
132. Ginsberg S.D. Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Psychiatry 13 (2005) 1052-1061
133. Ginsberg S.D., and Che S. RNA amplification in brain tissues. Neurochem Res 27 (2002) 981-992
134. Ginsberg S.D., Crino P.B., Hemby S.E., Weingarten J.A., Lee V.M.-Y., Eberwine J.H., et al. Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 45 (1999) 174-181
135. Ginsberg S.D., Hemby S.E., Lee V.M.-Y., Eberwine J.H., and Trojanowski J.Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48 (2000) 77-87
136. Hemby S.E., Ginsberg S.D., Brunk B., Arnold S.E., Trojanowski J.Q., and Eberwine J.H. Gene expression profile for schizophrenia. discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry 59 (2002) 631-640
137. Hemby S.E., Trojanowski J.Q., and Ginsberg S.D. Neuron-specific age-related decreases in dopamine receptor subtype mRNAs. J Comp Neurol 456 (2003) 176-183
138. Mufson E.J., Counts S.E., and Ginsberg S.D. Single cell gene expression profiles of nucleus basalis cholinergic neurons in Alzheimer's disease. Neurochem Res 27 (2002) 1035-1048
139. Eberwine J., Yeh H., Miyashiro K., Cao Y., Nair S., Finnell R., et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 89 (1992) 3010-3014
140. Eberwine J., Kacharmina J.E., Andrews C., Miyashiro K., McIntosh T., Becker K., et al. mRNA expression analysis of tissue sections and single cells. J Neurosci 21 (2001) 8310-8314
141. Eberwine J., Belt B., Kacharmina J.E., and Miyashiro K. Analysis of subcellularly localized mRNAs using in situ hybridization, mRNA amplification, and expression profiling. Neurochem Res 27 (2002) 1065-1077
142. van Gelder R., von Zastrow M., Yool A., Dement W., Barchas J., and Eberwine J. Amplified RNA (aRNA) synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87 (1990) 1663-1667
143. Cheetham J.E., Coleman P.D., and Chow N. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. J Neurosci Methods 77 (1997) 43-48
144. Chow N., Cox C., Callahan L.M., Weimer J.M., Guo L., and Coleman P.D. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc Natl Acad Sci USA 95 (1998) 9620-9625
145. Mufson EJ, Counts SE, Che S, Ginsberg SD. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Prog Neurobiol (in press).
146. Ginsberg SD, Mirnics K. Functional genomics methodologies. Prog Neurobiol (in press).
147. Dafforn A., Chen P., Deng G., Herrler M., Iglehart D., Koritala S., et al. Linear mRNA amplification from as little as 5 ng total RNA for global gene expression analysis. BioTechniques 37 (2004) 854-857
148. Kurn N., Chen P., Heath J.D., Kopf-Sill A., Stephens K.M., and Wang S. Novel isothermal, linear nucleic acid amplification systems for highly multiplexed applications. Clin Chem 51 (2005) 1973-1981
149. Che S., and Ginsberg S.D. Amplification of transcripts using terminal continuation. Lab Invest 84 (2004) 131-137
150. Che S, Ginsberg SD. RNA amplification methodologies. In: Trends in RNA research. Hauppauge, NY: Nova Science Publishing (in press).
151. Brown P.O., and Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 21 (1999) 33-37
152. Eisen M.B., and Brown P.O. DNA arrays for analysis of gene expression. Methods Enzymol 303 (1999) 179-205
153. Schena M., Shalon D., Davis R.W., and Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
154. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., et al. Expression monitoring by hybridization to high density oligonucleotide arrays. Nat Biotechnol 14 (1996) 1675-1680
155. Olson N.E. The microarray data analysis process. from raw data to biological significance. NeuroRx 3 (2006) 371-381
156. Almudevar A., Klebanov L.B., Qiu X., Salzman P., and Yakovlev A.Y. Utility of correlation measures in analysis of gene expression. NeuroRx 3 (2006) 382-393
157. Gygi S.P., Rochon Y., Franza B.R., and Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19 (1999) 1720-1730
158. Ginsberg S.D., Galvin J.E., Chiu T.-S., Lee V.M.-Y., Masliah E., and Trojanowski J.Q. RNA sequestration to pathological lesions of neurodegenerative disorders. Acta Neuropathol 96 (1998) 487-494
159. Topaloglu H., and Sarnat H.B. Acridine orange-RNA fluorescence maturing neurons in the perinatal rat brain. Anat Rec 224 (1989) 88-93
160. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
161. Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17 (1996) 673-680
162. Sarnat H.B., Curry B., Rewcastle N.B., and Trevenen C.L. Gliosis and glioma distinguished by acridine orange. Can J Neurol Sci 14 (1987) 31-35
163. Burbach G.J., Dehn D., Nagel B., Del Turco D., and Deller T. Laser microdissection of immunolabeled astrocytes allows quantification of astrocytic gene expression. J Neurosci Methods 138 (2004) 141-148
164. Burbach G.J., Dehn D., Del Turco D., Staufenbiel M., and Deller T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia 48 (2004) 76-84
165. Harrison P.J., Barton A.J., Najlerahim A., McDonald B., and Pearson R.C. Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease. Psychol Med 21 (1991) 855-866
166. Griffin W.S., Ling C., White C.L., and Morrison-Bogorad M. Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer's disease. Alzheimer Dis Assoc Dis 4 (1990) 69-78
167. Liu F., Grundke-Iqbal I., Iqbal K., and Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22 (2005) 1942-1950
168. Vogelsberg-Ragaglia V., Schuck T., Trojanowski J.Q., and Lee V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168 (2001) 402-412
169. Goedert M., Jakes R., Qi Z., Wang J.H., and Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates t protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem 65 (1995) 2804-2807
170. Joyce J.N., Kaeger C., Ryoo H., and Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neurosci Lett 154 (1993) 171-174
171. Ryoo H.L., and Joyce J.N. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer's disease. J Comp Neurol 348 (1994) 94-110
172. Rinne J.O., Lonnberg P., and Marjamaki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res 508 (1990) 349-352
173. Volkow N.D., Wang G.J., Fowler J.S., Ding Y.S., Gur R.C., Gatley J., et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 44 (1998) 143-147
174. Amenta F., Mignini F., Ricci A., Sabbatini M., Tomassoni D., and Tayebati S.K. Age-related changes of dopamine receptors in the rat hippocampus. a light microscope autoradiography study. Mech Aging Dev 122 (2001) 2071-2083
175. Gutala R.V., and Reddy P.H. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. J Neurosci Methods 132 (2004) 101-107
176. Callahan L.M., Vaules W.A., and Coleman P.D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer's disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 58 (1999) 275-287
177. Heffernan J.M., Eastwood S.L., Nagy Z., Sanders M.W., McDonald B., and Harrison P.J. Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp Neurol 150 (1998) 235-239
178. Shimohama S., Kamiya S., Taniguchi T., Akagawa K., and Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 236 (1997) 239-242
179. Sze C.I., Troncoso J.C., Kawas C., Mouton P., Price D.L., and Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer's disease. J Neuropathol Exp Neurol 56 (1997) 933-944
180. Sze C.I., Bi H., Kleinschmidt-DeMasters B.K., Filley C.M., and Martin L.J. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 175 (2000) 81-90
181. Cataldo A.M., Paskevich P.A., Kominami E., and Nixon R.A. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer's disease. Proc Natl Acad Sci USA 88 (1991) 10998-11002
182. Cataldo A.M., Barnett J.L., Berman S.A., Li J., Quarless S., Bursztajn S., et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain. evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14 (1995) 671-680
183. Cataldo A.M., Barnett J.L., Picroni C., and Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease. neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J Neurosci 17 (1997) 6142-6151
184. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., et al. Macroautophagy. a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171 (2005) 87-98
185. Nixon R.A. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 26 (2005) 373-382
186. Cataldo A.M., Hamilton D.J., Barnett J.L., Paskevich P.A., and Nixon R.A. Properties of the endosomal-lysosomal system in the human central nervous system. disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci 16 (1996) 186-199
187. Mesulam M.M., Mufson E.J., Levey A.I., and Wainer B.H. Cholinergic innervation of cortex by the basal forebrain. cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214 (1983) 170-197
188. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
189. Baxter M.G., and Chiba A.A. Cognitive functions of the basal forebrain. Curr Opin Neurobiol 9 (1999) 178-183
190. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
191. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., et al. Neurochemical correlates of dementia severity in Alzheimer's disease. relative importance of the cholinergic deficits. J Neurochem 64 (1995) 749-760
192. Auld D.S., Kornecook T.J., Bastianetto S., and Quirion R. Alzheimer's disease and the basal forebrain cholinergic system. relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68 (2002) 209-245
193. Galvin J.E., and Ginsberg S.D. Expression profiling in the aging brain. a perspective. Aging Res Rev 4 (2005) 529-547
194. Galvin J.E., and Ginsberg S.D. Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Dis Assoc Disord 18 (2004) 264-269
195. Mesulam M., Shaw P., Mash D., and Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55 (2004) 815-828
196. Counts S.E., and Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer's disease. J Neuropathol Exp Neurol 64 (2005) 263-272
197. Mufson E.J., Ma S.Y., Cochran E.J., Bennett D.A., Beckett L.A., Jaffar S., et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 427 (2000) 19-30
198. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Beckett L.A., Aggarwal N.T., et al. Natural history of mild cognitive impairment in older persons. Neurology 59 (2002) 198-205
199. King M.E., Gamblin T.C., Kuret J., and Binder L.I. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem 74 (2000) 1749-1757
200. Levy S.F., Leboeuf A.C., Massie M.R., Jordan M.A., Wilson L., and Feinstein S.C. Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. implications for neurodegeneration. J Biol Chem 280 (2005) 13520-13528
201. Chambers C.B., Lee J.M., Troncoso J.C., Reich S., and Muma N.A. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46 (1999) 325-332
202. de Silva R., Lashley T., Gibb G., Hanger D., Hope A., Reid A., et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29 (2003) 288-302
203. Arai T., Ikeda K., Akiyama H., Tsuchiya K., Iritani S., Ishiguro K., et al. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 105 (2003) 489-498
204. Fujino Y., Wang D.S., Thomas N., Espinoza M., Davies P., and Dickson D.W. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol 64 (2005) 209-214
205. Zhukareva V., Shah K., Uryu K., Braak H., Del Tredici K., Sundarraj S., et al. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease. a comparative study. Am J Pathol 161 (2002) 1135-1141
206. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., and DeKosky S.T. Human cholinergic basal forebrain. chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26 (2003) 233-242
207. Sofroniew M.V., Howe C.L., and Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24 (2001) 1217-1281
208. Counts S.E., Nadeem M., Wuu J., Ginsberg S.D., Saragovi H.U., and Mufson E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 56 (2004) 520-531
209. Colantuoni C., Purcell A.E., Bouton C.M., and Pevsner J. High throughput analysis of gene expression in the human brain. J Neurosci Res 59 (2000) 1-10
210. Serafini T. Of neurons and gene chips. Curr Opin Neurobiol 9 (1999) 641-644